Business Context and Reporting Period
This Form 8-K Current Report from Prelude Therapeutics Inc. (PRLD) covers events occurring on April 8, 2024. The filing addresses significant changes in executive leadership, specifically the departure of the Chief Financial Officer and the appointment of an interim successor.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and personnel changes.
- Severance Payment: $333,750 in total gross cash severance (representing nine months of base salary).
- Consulting Rate: $500 per hour for interim consulting services.
- Consulting Period: April 10, 2024, through October 4, 2024.
Material Changes
The primary material change is the departure of Laurent Chardonnet as Chief Financial Officer, effective April 8, 2024. Concurrently, the Company entered into a Consulting Agreement and a Separation Agreement with Mr. Chardonnet. Additionally, Bryant D. Lim, the Company's Chief Legal Officer and Corporate Secretary, was appointed as Interim Chief Financial Officer effective April 8, 2024.
Outlook, Risks, and Management Commentary
Management expressed appreciation for Mr. Chardonnet's contributions. The Company is conducting an ongoing search for a permanent Chief Financial Officer. Mr. Lim will serve in the interim role while continuing his existing duties as Chief Legal Officer and Corporate Secretary. The filing notes that Mr. Chardonnet's equity awards will continue to vest during the consulting period, subject to compliance with the Separation Agreement and restrictive covenants.
Investor Verification Checklist
- Verify the total cost of the severance package ($333,750) and the potential consulting fees based on the $500/hour rate.
- Confirm the timeline for the search for a permanent Chief Financial Officer.
- Review the attached Exhibits 10.1 (Consulting Agreement) and 10.2 (Separation Agreement) for specific restrictive covenants and release terms.
- Monitor future filings for any amendments regarding compensation arrangements for the interim CFO, Bryant D. Lim.